Scandinavian Biopharma strengthens its vaccine portfolio in the field of diarrhoeal disease by in-licencing a Campylobacter vaccine technology from Canadian company, VaxAlta Inc.
Scandinavian Biopharma has strengthened its vaccine portfolio by the addition of an innovative preclinical project for the development of a new Campylobacter jejuni vaccine. Scandinavian Biopharma will have the global rights for a Campylobacter jejuni vaccine technology developed by VaxAlta.